Santa Cruz Biotechnology (SCBT)

MEDICAL

Fauna | June 15, 2022

Fauna Bio, a biotechnology company pioneering the fields of comparative, computational and translational genomics, is celebrating its fourth birthday this month with the release of Centaur, a knowledge graph that is the first of its kind to visualize the intersection between animal gene expression data and human diseases in one comprehensive map. With Centaur, Fauna Bio is able to more rapidly identify human disease indications and targets to generate new therapeutic solutions for some of the mo...

INDUSTRIAL IMPACT

Celyad Oncology | August 01, 2022

Celyad Oncology SA a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell therapies for cancer, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the CYAD-101-002 Phase 1b trial after the Company made changes to the eligibility criteria for the trial. “We are pleased that the FDA lifted the clinical hold on this trial. We remain confident in the p...

Angstrom Bio | October 14, 2020

Angstrom Bio, Inc. today announces the launch of AMPD™, its nanopore sequencing and machine learning powered platform for high-accuracy, high-frequency, low-cost COVID-19 and respiratory pathogen testing. AMPD leverages the extreme resolution and bandwidth of nanopore sequencing to provide the accuracy and volume necessary to detect the earliest stages of exposure to pathogens like SARS-CoV-2 and influenza and to enable schools and places of work to reopen safely and confidently. Angstrom ...

BioSpace | February 17, 2020

Neuropore Therapies, Inc., a biopharmaceutical company discovering and developing novel therapeutics for the treatment of neurodegenerative disorders, announced today that it has been awarded a $500,000 grant from The ALS Association to support the preclinical evaluation and development of its leading Toll-Like Receptor 2 (TLR2) antagonist NPT1220-312 for the treatment of amyotrophic lateral sclerosis. The grant has been made through the Association’s Lawrence and Isabel Barnett Drug Devel...